Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...

PITTSBURGH — Patients with Type 1 diabetes are getting help managing it with a new device. Families in Pittsburgh have been waiting a long time for the Omnipod 5 and it wasn’t very easy to get at ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

The tubeless Omnipod 5 automated insulin delivery system, launched in the United Kingdom in 2023, was associated with improved time in range (TIR) at 1 year, with no increase in time below range and ...

Insulet PODD delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall. Though management ...

Insulet PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, its heavy reliance on the Omnipod System and a ...

Q2 revenue rises 32.9% Y/Y to $649.1 million, beating estimates and topping guidance range. Insulet raises FY25 sales outlook to $2.57 billion–$2.63 billion, above prior view of $2.47 billion–$2.53 ...